TD Asset Management Inc Sells 20,557 Shares of Amgen Inc. $AMGN

TD Asset Management Inc lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 5.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 385,720 shares of the medical research company’s stock after selling 20,557 shares during the quarter. TD Asset Management Inc’s holdings in Amgen were worth $108,850,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of AMGN. Vanguard Group Inc. increased its position in Amgen by 0.3% in the third quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock worth $15,204,047,000 after buying an additional 165,281 shares during the last quarter. State Street Corp lifted its position in shares of Amgen by 0.6% during the 2nd quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock valued at $8,196,775,000 after buying an additional 177,035 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Amgen by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock valued at $3,619,489,000 after buying an additional 291,271 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Amgen by 5.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after acquiring an additional 687,735 shares during the period. Finally, Laurel Wealth Advisors LLC increased its holdings in Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after acquiring an additional 6,676,575 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AMGN. TD Cowen reiterated a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. DZ Bank upped their price target on shares of Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Argus raised their price objective on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Barclays began coverage on shares of Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price on the stock. Finally, Mizuho raised their price target on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $351.76.

Amgen Price Performance

NASDAQ:AMGN opened at $384.33 on Thursday. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $387.49. The stock has a fifty day moving average of $346.58 and a 200 day moving average of $318.34. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The firm has a market capitalization of $207.18 billion, a price-to-earnings ratio of 27.01, a P/E/G ratio of 3.79 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 2.6%. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.